Synthesis: pCR as an endpoint

Evidence grades (GRADE-adapted): A high — multiple well-conducted RCTs or systematic reviews converge. B moderate — single pivotal RCT or consistent observational evidence. C limited — single observational study, mechanistic, or expert consensus. D preclinical / hypothesis-generating.

What pCR is and isn't

Pathologic complete response is the absence of residual invasive carcinoma in the breast and axillary lymph nodes at the time of definitive surgery following neoadjuvant systemic therapy. The most widely used definition (and the one used in FDA labeling) is ypT0/Tis ypN0 — no invasive tumor in the breast (residual ductal carcinoma in situ allowed) and no invasive tumor in the lymph nodes. A stricter alternative (ypT0 ypN0; no DCIS allowed) has been used in some trials but is less standard.

The conceptual frame: a tumor that completely disappears under chemotherapy treatment was profoundly sensitive to the regimen. A tumor with residual disease at surgery was less sensitive, harbors residual clones that the systemic therapy didn't eradicate, and has higher likelihood of micrometastatic disease that will manifest as distant recurrence later. This frame is well-supported in TNBC specifically: TNBC patients who achieve pCR have substantially better long-term outcomes than those with residual disease, with the gap larger in TNBC than in HR+ breast cancer.

CTNeoBC 2014 — the pooled analysis that established pCR

Cortazar and colleagues, on behalf of the FDA, conducted a pooled patient-level analysis of 11,955 patients across 12 neoadjuvant chemotherapy trials, examining the relationship between pCR and long-term outcomes by breast cancer subtype^[1]A. The analysis was commissioned by the FDA to evaluate whether pCR could serve as a surrogate endpoint for accelerated drug approval in early-stage breast cancer.

Patient-level prognosis

Across all subtypes, pCR was strongly associated with improved event-free survival and overall survival. The magnitude varied by subtype:

• TNBC: EFS HR 0.24 (pCR vs no-pCR); OS HR 0.16. Largest pCR-associated benefit of any subtype.
• HER2-positive (HR+): EFS HR 0.30; OS HR 0.35. Substantial benefit.
• HER2-positive (HR−): EFS HR 0.25; OS HR 0.27. Substantial benefit.
• HR+/HER2-negative (luminal A-like): EFS HR 0.49; OS HR 0.54. Modest benefit.
• HR+/HER2-negative (luminal B-like): EFS HR 0.40; OS HR 0.43. Intermediate benefit.

The take-away: pCR's patient-level prognostic value is strongest in TNBC and HER2-positive disease, where treatment effects on tumor biology translate most directly to outcomes. In HR+/HER2− disease, pCR remains prognostic but with a smaller effect — consistent with the slower-growing biology of luminal tumors where chemotherapy isn't the main mode of action.

Trial-level surrogacy

Despite the patient-level association, the same CTNeoBC analysis found weaker correlations at the trial level: improvements in pCR rates between treatment arms within a trial did not consistently predict improvements in long-term outcomes between those same arms. The pooled regression of trial-level pCR change vs trial-level EFS change had R² of approximately 0.30 — a relationship but not a strong one. This distinction matters for regulatory and clinical-trial-design reasons: pCR can be used as a faster surrogate for individual patient prognostication, but using a pCR improvement in one trial to predict EFS/OS improvement in subsequent practice requires caution.

Residual cancer burden (RCB)

The pCR / not-pCR dichotomy treats all residual disease as equivalent. Symmans and colleagues at MD Anderson developed the Residual Cancer Burden (RCB) classification, a continuous quantitative measure of residual disease that captures bidirectional tumor size, percentage of cancer cellularity, number of involved lymph nodes, and size of the largest nodal metastasis^[2]A. RCB is reported as both a continuous index and a categorized form (RCB-0 = pCR; RCB-I = minimal; RCB-II = moderate; RCB-III = extensive).

RCB has been validated as prognostic in TNBC across multiple cohorts. The 2017 Symmans long-term update reported^[3]A:

• RCB-0 (pCR): excellent prognosis — ~10-year recurrence-free survival 90–95%
• RCB-I: very good prognosis — ~10-year RFS 85% (similar to pCR)
• RCB-II: intermediate prognosis — ~10-year RFS 65–70%
• RCB-III: poor prognosis — ~10-year RFS 30–40%

Implication: patients with RCB-I or low RCB-II have prognoses much closer to pCR than to RCB-III, supporting the idea that residual disease is heterogeneous and that some "no-pCR" patients are at relatively low risk while others are at very high risk. RCB is increasingly reported alongside pCR in TNBC pathology synoptic reports.

pCR-driven regulatory accelerated approval

In 2014, the FDA issued guidance on the use of pCR for accelerated approval in high-risk early-stage breast cancer, predicated in part on the CTNeoBC analysis^[4]A. The framework:

• pCR can support accelerated approval if (a) the improvement is large, (b) the patient population has high baseline risk, and (c) the manufacturer commits to confirmatory event-time studies.
• Full approval requires demonstration of long-term benefit (EFS, iDFS, or OS).

The pembrolizumab approval for KEYNOTE-522-defined high-risk early-stage TNBC followed this pathway: initial FDA approval in July 2021 based on the pCR co-primary endpoint (Schmid 2020 NEJM); confirmatory full approval was anchored on the 2022 EFS update (Schmid 2022 NEJM) that confirmed the pCR-derived benefit translated to event-time outcomes^[5]A. KEYNOTE-522 is the most successful application of the pCR-accelerated-approval pathway in TNBC.

Less successful applications:

• Bevacizumab in early-stage HER2-positive disease — positive pCR effect did not translate to EFS/OS benefit; approval not granted.
• Several other neoadjuvant trial readouts had positive pCR but failed to confirm long-term benefit, reinforcing the trial-level surrogacy caution.

pCR-driven adjuvant decision-making

pCR achievement (or not) is now the most important factor in adjuvant therapy decisions for early-stage TNBC patients who received neoadjuvant chemo + IO:

• pCR achievers — per the KEYNOTE-522 protocol, continue adjuvant pembrolizumab to complete the planned 1-year exposure. No additional chemotherapy is given. Several de-escalation trials (e.g., OptimICE-pCR) are testing whether the adjuvant pembrolizumab continuation can be safely omitted.
• Residual disease (no pCR) — continue adjuvant pembrolizumab AND consider escalation: adjuvant capecitabine (CREATE-X precedent), adjuvant olaparib (OlympiA, for germline-BRCA-mutated), or adjuvant sacituzumab govitecan / trastuzumab deruxtecan (under investigation in SASCIA, TROPICS-08, ASCENT-05).

See the adjuvant residual disease synthesis for detail on the escalation options.

De-escalation trials using pCR as a gate

An emerging trial-design theme uses pCR achievement as a gate for treatment de-escalation: patients who achieve pCR after a shortened or less intensive course of treatment can safely stop earlier; non-achievers receive additional treatment. Examples:

• KEYNOTE-522 de-escalation arms — testing shorter pembrolizumab courses for pCR achievers.
• Anthracycline-sparing regimens — pCR rate with carboplatin + taxane + pembro (no anthracycline) being tested in several phase II trials; pCR is the gating endpoint.
• Carboplatin-sparing regimens — conversely, testing whether the carboplatin contribution to the KEYNOTE-522 regimen is dispensable.
• Local-therapy de-escalation — very-high-TIL or extreme-pCR-achiever patients being studied for omission of axillary surgery or breast radiation.

These trials read out over the next 2–5 years and have the potential to reshape early-stage TNBC management.

Evidence table

Limitations of pCR as an endpoint

• Trial-level surrogacy is imperfect. A drug that improves pCR is not guaranteed to improve EFS or OS in subsequent confirmatory trials. The bevacizumab and several other examples illustrate this. Surrogate-endpoint debate continues.
• RCB-I is essentially equivalent to pCR for prognosis but is captured as "no pCR" in dichotomous endpoints. Using pCR as the binary outcome misclassifies these low-residual-disease patients as treatment failures.
• HR+/HER2-negative pCR rates are low, making pCR a less practical endpoint in luminal TNBC trials. Most TNBC trials are restricted to or analyzed predominantly in the basal-like subset where chemo-IO sensitivity is highest.
• Pathologic assessment requires careful methodology. Comprehensive sampling of the tumor bed at surgery is required; inadequate sampling can produce false pCR designations.
• Patients with extensive baseline disease may have pCR but still have residual micrometastatic disease. The pCR signal is breast/nodes only; cells circulating in blood or in micrometastatic deposits elsewhere aren't sampled.

Open questions and active investigation

• Will ctDNA-based MRD detection refine pCR? Circulating tumor DNA detection after neoadjuvant therapy provides additional information beyond surgical pathology. Patients with ctDNA-positive status post-treatment may have higher recurrence risk regardless of pCR status. Whether ctDNA should replace, complement, or refine pCR-based decisions is being tested.
• RCB-driven escalation/de-escalation algorithms. Replacing the pCR / not-pCR dichotomy with continuous RCB or RCB categories in clinical decision-making could refine treatment intensity. RCB-I patients might safely receive less adjuvant treatment than RCB-II/III patients.
• Pathologic complete response and biology — do non-pCR achievers harbor specific molecular features that predict recurrence? Targeted profiling of residual disease (sequencing, transcriptomics) is generating biomarker hypotheses for which adjuvant therapy to choose.
• Long-term safety considerations in pCR achievers. If pCR achievers can safely receive less intensive adjuvant therapy, the long-term consequences (less cardiotoxicity, less neurotoxicity, less ILD risk) are substantive quality-of-life improvements. The de-escalation trial readouts will determine how aggressively this is pursued.
• Standardization of RCB reporting. RCB requires specific pathologic methodology that not all centers implement. Standardization is increasing but uneven.

For the KEYNOTE-522 trial that uses pCR as a co-primary endpoint, see the KEYNOTE-522 synthesis. For residual-disease adjuvant options, see the adjuvant residual disease synthesis. For the patient-layer companion, see Treatment options.

References

Each citation links to the original publication via DOI. The same records are searchable in the evidence library by title or DOI.

1. Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164–172. doi:10.1016/S0140-6736(13)62422-8. ↩
2. Symmans WF, Peintinger F, Hatzis C, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007;25(28):4414–4422. doi:10.1200/JCO.2007.10.6823. ↩
3. Symmans WF, Wei C, Gould R, et al. Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden Classification. J Clin Oncol. 2017;35(10):1049–1060. doi:10.1200/JCO.2015.63.1010. ↩
4. US Food and Drug Administration. Pathological Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer: Use as an Endpoint to Support Accelerated Approval. Guidance for Industry. 2014. ↩
5. Schmid P, Cortes J, Dent R, et al. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer (KEYNOTE-522). N Engl J Med. 2022;386(6):556–567. doi:10.1056/NEJMoa2112651. ↩

Last reviewed: 2026-06-04. Researcher-layer synthesis page. Evidence grades follow the GRADE-adapted rubric defined at the top of this page.